Advancements in technology and DNA sequencing are making precision medicine more accessible and affordable driving increasing interest from providers and consumers. The promise of more data-driven care and early detection can help health systems advance strategic goals like reducing the cost of care and attracting consumers. While some early adopters have seen ROI, there remains uncertainty about how best to scale these programs and create a business line to support the necessary investment, particularly in these difficult economic times.

During this panel discussion hosted by The Academy several industry partners in the precision medicine and genomics space will discuss how to build a genomics program to attract consumers and generate additional revenue for the system.

Panelists include:

• Haibo Lu, Co-Founder and Chief Product Officer, Cancer IQ
• Lisa Alderson, CEO & Co-founder, Genome Medical
• Dr. James Lu, CEO & Co-founder, Helix
• Dr. Phil Febbo, CMO, Illumina